Drug Trial Radar · NCT05608876
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Nov 3, 2022
Primary completion
Jul 31, 2025
Study completion Aug 2026
Sponsor
- Lead sponsor
- QBiotics Group LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.
Conditions
- Head and Neck Cancer
Interventions
Tigilanol TiglateDrug
Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tumour ResponseTime frame: 72 weeks
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
The Kinghorn Cancer Centre
Sydney, New South Wales, Australia
Metro South Hospital and Health Service, via the Princess Alexandra Hospital
Brisbane, Queensland, Australia
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Cardiff and Vale University Health Board - University Hospital of Wales (UHW)
Cardiff, Cardiff, United Kingdom
East and North Hertfordshire NHS Trust (Incorporating Mount Vernon Cancer Centre) of Lister Hospital
Stevenage, Hertfordshire, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.